Vera Therapeutics Croissance future

Future contrôle des critères 0/6

Vera Therapeutics devrait augmenter ses bénéfices et ses revenus de 17% et de 83.5% par an respectivement, tandis que le BPA devrait croître de croître de 20.9% par an.

Informations clés

17.0%

Taux de croissance des bénéfices

20.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	83.5%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:VERA - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	50	-233	-213	-193	8
12/31/2025	N/A	-207	-181	-174	8
12/31/2024	N/A	-158	-132	-146	8
9/30/2024	N/A	-134	-121	-121	N/A
6/30/2024	N/A	-108	-107	-107	N/A
3/31/2024	N/A	-94	-100	-100	N/A
12/31/2023	N/A	-96	-92	-92	N/A
9/30/2023	N/A	-103	-88	-88	N/A
6/30/2023	N/A	-107	-84	-84	N/A
3/31/2023	N/A	-102	-85	-85	N/A
12/31/2022	N/A	-89	-68	-68	N/A
9/30/2022	N/A	-73	-58	-53	N/A
6/30/2022	N/A	-56	-45	-40	N/A
3/31/2022	N/A	-45	-34	-29	N/A
12/31/2021	N/A	-33	-29	-24	N/A
9/30/2021	N/A	-59	-45	-45	N/A
6/30/2021	N/A	-55	-42	-42	N/A
3/31/2021	N/A	-56	-37	-37	N/A
12/31/2020	N/A	-53	-35	-35	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: VERA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: VERA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: VERA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: VERA ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: VERA ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de VERA devrait être élevé dans 3 ans

Vera Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 17% to US$55.80

Price target increased by 36% to US$32.11

Price target increased by 12% to US$22.14

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

Recent updates

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts